Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?

ABSTRACT: Lung cancer is one of the most common human malignancies and the leading cause of cancer-related death worldwide. Novel therapeutic approaches, like targeted therapies against specific molecular alterations and immunotherapy, have revolutionized in the last decade the oncological outcomes in patients affected by non-small cell lung cancer (NSCLC). The advent of immunotherapy for the treatment of NSCLC has significantly improved overall and progression-free survival, as well as the patient's quality of life in comparison to traditional chemotherapy. Currently, it is estimated that long-term survival can be achieved in more than 15% of NSCLC patients treated with immunotherapy. Therefore, the optimal duration of immunotherapy in long survivors needs to be established to avoid overtreatment,

SUBMITTER: Putzu C 

PROVIDER: S-EPMC9913378 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature